Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 126 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2014', provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 9
Therapeutics Development 10
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 10
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis 11
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 12
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 17
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 18
AstraZeneca PLC 18
Athersys, Inc. 19
CardioVascular BioTherapeutics, Inc. 20
Celgene Corporation 21
Ligand Pharmaceuticals, Inc. 22
Cytokinetics, Inc. 23
Cytomedix, Inc. 24
ReNeuron Group plc 25
Genovate Biotechnology Co., LTD. 26
Betagenon AB 27
Proteon Therapeutics, Inc. 28
Diffusion Pharmaceuticals LLC 29
Theravasc, Inc. 30
ViroMed Co., Ltd. 31
miRagen Therapeutics, Inc. 32
RegenoCELL Therapeutics, Inc. 33
Multi Gene Vascular Systems Ltd 34
Cardiolynx AG 35
Recardio GmbH 36
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
ticagrelor - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
clopidogrel bisulfate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ALD-301 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
tirasemtiv - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
transcrocetinate sodium - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
VM-202 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
sodium nitrite - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SYN-20112312RU - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cilostazol SR - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MultiGeneAngio - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CVBT-141C - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PRT-201 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
O-304 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MultiGeneGraft - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
PDA-002 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MultiStem - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ReN-009 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MGN-6114 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Annexin A-5 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
REC-03 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
AEM-28 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Autologous Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ELS-140 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
(organic nitrate + cilostazol) ER - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 84
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 114
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 115
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 116
Featured News & Press Releases 116
Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session 116
Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 118
Feb 28, 2013: Adventrx Pharma To Develop ANX-188 For Complications Of Arterial Disease 118
Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 119
Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In Patients Suffering From Peripheral Artery Disease 120
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells 120
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 121
Jul 17, 2012: AstraZeneca To Initiate New Study Of BRILINTA In Patients With Peripheral Artery Disease 121
Jun 20, 2012: New Platelet Blocker Reduces Blood Clots And Artery-Opening Procedures, Study Finds 123
Jun 15, 2012: ReNeuron Presents Positive Preclinical Data Of ReN009 At 10th Annual Meeting Of International Society For Stem Cell Research 124
Appendix 125
Methodology 125
Coverage 125
Secondary Research 125
Primary Research 125
Expert Panel Validation 125
Contact Us 126
Disclaimer 126

List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2014 10
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca PLC, H2 2014 18
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H2 2014 19
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2014 20
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H2 2014 21
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 22
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cytokinetics, Inc., H2 2014 23
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cytomedix, Inc., H2 2014 24
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ReNeuron Group plc, H2 2014 25
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Genovate Biotechnology Co., LTD., H2 2014 26
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H2 2014 27
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H2 2014 28
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals LLC, H2 2014 29
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H2 2014 30
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H2 2014 31
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H2 2014 32
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by RegenoCELL Therapeutics, Inc., H2 2014 33
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2014 34
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Cardiolynx AG, H2 2014 35
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Assessment by Combination Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 44
Number of Products by Stage and Route of Administration, H2 2014 46
Number of Products by Stage and Molecule Type, H2 2014 48
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H2 2014 84
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2 2014 114
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H2 2014 115